The company has created a platform technology to expand hematopoietic stem cells, enabling the development of cell therapy products for patients with blood disorders. Their technology has various applications, including gene/cell therapy using gene editing on hematopoietic stem cells. Celaid Therapeutics aims to improve the quality of life for patients, their families, and stem cell donors worldwide. Founded in 2020 and based in Tokyo, Japan, the company specializes in manufacturing and selling regenerative medicine products utilizing human hematopoietic stem cells.